Medkart Welcomes Government’s 30% Margin Cap on 137 Cancer Medicines, Urges Patients to Check Revised Prices

Prices of selected anti-cancer drugs are set to fall by up to 70%; Medkart’s comparison tools help patients find the most affordable option.

INDIA, November 10, 2026 /EINPresswire.com/ -- With the government set to cap trade margins on 137 anti-cancer medicines from November 9, Medkart, one of India’s largest generic-first pharmacy chains, has welcomed the move as a significant step towards making cancer care more affordable, and is urging patients and caregivers to check revised prices before their next refill.

The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, announced on October 17 that trade margins on 137 selected non-scheduled anti-cancer medicines will be capped at 30%. Prices of these medicines are expected to fall by up to 70%, though the actual reduction will vary by medicine and formulation depending on the existing price structure. The list includes medicines used in immunotherapy and in the treatment of breast, prostate, colon, ovarian and cervical cancers. The government estimates that patients could save around ₹2,500 crore annually.
The move builds on the NPPA’s 2019 intervention on 42 anti-cancer medicines. Manufacturers have been directed to publish revised prices, and retailers and hospitals must charge the updated rates and display the revised price lists from November 9.

“For many families, the cost of cancer treatment is not a one-time burden — it returns every month, sometimes for years. Capping trade margins brings relief right at the pharmacy counter, and we welcome it. Our focus at Medkart is to make sure every patient can see their options clearly and pay a fair price, whether that is a branded medicine at its revised MRP or a clinically equivalent generic,” said [Name], [Designation], Medkart.

How Medkart is helping patients

Through the Medkart app and website, patients can upload prescriptions, browse prices across generic options, and get medicines delivered to their door. A dedicated comparison page lets patients look up a branded medicine and see how it compares with its generic equivalent — or simply search a medicine by name to get a recommended “smart choice” generic alternative, often available for up to 80% less. Medkart pharmacists are trained to walk patients through these options. [Medkart stocks a range of oncology medicines and has updated its pricing to reflect the revised MRPs effective November 9.]

What patients should know
● The cap applies to the 137 identified medicines, not to every cancer drug. Patients should check whether their prescribed medicine is on the NPPA list.
● Revised prices can be checked on the NPPA website and the Pharma Sahi Daam app, and retailers are required to display updated price lists.
● Patients can use Medkart’s comparison page or search by medicine name to see their options.
● Cancer medicines should never be stopped or switched without consulting the treating oncologist.

About Medkart Pharmacy
Medkart Pharmacy is a generic-first pharmacy chain offering quality-approved generics through its stores and online platform under the Medkart Assured framework, covering Schedule M compliance, plant audits, and dual third-party testing.] To know more or order medicines online, visit www.medkart.in or download the Medkart app from the Play Store or App Store.

Debashish Baidya
Medkart Pharmacy PVT LTD
+91 98256 49399
Visit us on social media:
LinkedIn